Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses

BACKGROUND: Romidepsin is a structurally unique, potent, bicyclic class 1 selective histone deacetylase inhibitor approved by the US Food and Drug Administration for the treatment of patients with cutaneous T-cell lymphoma who have received ≥ 1 prior systemic therapy and patients with peripheral T-c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Coiffier, Bertrand, Pro, Barbara, Prince, H Miles, Foss, Francine, Sokol, Lubomir, Greenwood, Matthew, Caballero, Dolores, Morschhauser, Franck, Wilhelm, Martin, Pinter-Brown, Lauren, Padmanabhan Iyer, Swaminathan, Shustov, Andrei, Nielsen, Tina, Nichols, Jean, Wolfson, Julie, Balser, Barbara, Horwitz, Steven
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2014
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4016573/
https://ncbi.nlm.nih.gov/pubmed/24456586
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-7-11
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars